DreamCIS, Inc. (KOSDAQ:223250)

South Korea · Delayed Price · Currency is KRW

3,100.00

-150.00 (-4.62%)

At close: Jun 26, 2026

-8.55% (1Y)

Market Cap	84.99B +18.3%
Revenue (ttm)	69.87B +14.7%
Net Income	6.16B +8.1%
EPS	258.62 +9.9%
Shares Out	24.60M
PE Ratio	13.36
Forward PE	7.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,460
Open	3,330.00
Previous Close	3,250.00
Day's Range	2,930.00 - 3,330.00
52-Week Range	2,930.00 - 8,640.00
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About DreamCIS

DreamCIS, Inc. operates as a clinical research organization in South Korea, Europe, China, Asia Pacific, the United States, and Canada. It offers clinical development services; standalone services, including biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary o... [Read more]

Industry Commercial Physical and Biological Research

Founded 2000

Employees 392

Stock Exchange KOSDAQ

Ticker Symbol 223250

Full Company Profile

Financial Performance

In 2025, DreamCIS's revenue was 66.63 billion, an increase of 13.60% compared to the previous year's 58.65 billion. Earnings were 7.13 billion, an increase of 34.97%.

Financial Statements